Antagonists of bmp and tgf.beta. signalling pathways
CA 2376675 A1 · Owner: Thomsen, Gerald H. · Inventors: Thomsen, Gerald H.; Wrana, Jeffrey
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides unique members of the Hect family of ubiquitin ligases that specifically target BMP and TGF.beta./activin pathway-specific Smads. The novel ligases have been named Smurf1 and Smurf2. They directly interact with Smads1 and 5 and Smad7, respectively, and regulate the ubiquitination turnover and activity of Smads and other proteins of these pathways. Smurf1 interferes with biological responses to BMP but not activin signalling. In , amphibian embryos Smurf1 inhibits endogenous BMP signals resulting in altered , pattern formation and cell fate specification in the mesoderm and ectoderm. The present invention provides a unique regulatory link between the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 12, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 12, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 12, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.